Indrayani Biotech Limited announced unaudited standalone earnings results for the first quarter ended June 30, 2021. For the quarter, net sales/revenue from operations were INR 142.440 million against INR 34.111 million a year ago. Total Income from Operations were INR 142.694 million against INR 34.820 million a year ago. Total profit for period was INR 7.937 million against loss of INR 63.398 million a year ago. Basic and diluted EPS from continuing operations were INR 0.23 against loss of INR 1.85 million a year ago.